Glucose transporter-1 (GLUT1) has been proposed as a prognosticator in various cancers associated with therapeutic resistance and immune evasion; however little data is available on the role of GLUT1 in cervical cancer. Most cervical cancers are caused by human papilloma virus (HPV), but studies on the treatment response and prognosis depending on the HPV subtype, are conflicting. This hypothesisgenerating study aims to investigate the prognostic impact of GLUT1 in cervical cancer, in conjunction with HPV subtype. Clinicopathologic factors, along with mRNA expression data were obtained using The Cancer Genome Atlas database. Tumor HPV status and immune cell scores were extracted from previous publications. In total, 298 patients were analyzed. High GLUT1 expression was associated with old age, squamous cell carcinoma, high tumor stage, pelvic lymph node metastases, and low hysterectomy rate. Multivariate survival analysis revealed that high GLUT1 expression (Hazard ratio (HR) 2.57, p = 0.002) and HPV16 subtype (HR 0.56, p = 0.033) were independent prognostic factors for overall survival. In the subgroup analysis, poor prognostic impact of high GLUT1 expression was maintained in HPV16-positive group (p < 0.001), but not in HPV16-negative group (p = 0.495). Decreased immune cell scores of CD8 + T cells, B cells, and Th1 cells by high GLUT1 expression were observed only in HPV16-positive group. In conclusion, these results suggested that GLUT1 expression and HPV16 subtype might have an independent prognostic value in cervical cancer. GLUT1-mediated immunomodulation might be an important cause of treatment failure, especially in HPV16-positive group.
enzymes, glucose transporter-1 (GLUT1), which facilitates glucose transport across the plasma membrane, has been reported to be a poor prognosticator in various cancers [10] [11] [12] . Previous meta-analysis suggested that the overexpression of GLUT1 was associated with enhanced invasiveness, proliferative potential, and decreased patients' survival 13 . However, little data is available for the prognostic significance of GLUT1 in cervical cancer. Therefore, to elucidate the effect of the combination of HPV genotypes and tumor metabolism, mediated by GLUT1, on the treatment outcomes and tumor microenvironment in cervical cancer, we analyzed these biomarkers in patients with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), using The Cancer Genome Atlas (TCGA) database.
Results
Patients' characteristics. Differential GLUT1 mRNA expression levels in tumor and normal tissues are shown according to TCGA classification in Supplemental Table 1 . CESC ranked second among the pan-cancers in terms of GLUT1 gene differential fold change (tumor over normal tissues).
The characteristics of the patients included in this study are presented in Supplemental Table 2 . Specifically, the mean age was 48 years (range 20-88 years). Squamous cell carcinoma was found in 247 (82.9%) patients, and adenocarcinoma was found in the remaining 51 patients (17.1%). About half of the patients had clinical stage I disease. The patients with diverse stage distribution received heterogeneous treatments including hysterectomy, radiotherapy, and/or chemotherapy. In terms of HPV infection, HPV16 was found in 164 (55.0%) patients, HPV18 in 39 (13.1%) patients, and other HPV subtypes in 70 (23.5%) patients. Only 18 patients were negative for all types of HPV (6.0%). Available follow-up data showed that recurrence occurred in 48 (16.1%) patients and death in 72 (24.2%) patients.
Upon subdivision of the patients into two groups based on the GLUT1 expression level, we found significant differences in characteristics (Table 1) . High GLUT1 expression was associated with age ≥50, squamous cell carcinoma, high tumor stage, pelvic lymph node metastases, low tumor grade, and low hysterectomy rate. On the contrary, when the patients were divided into two groups based on HPV16 positivity, we did not find association with clinicopathologic factors, except for a low tumor grade and age <50 (Supplemental Table 3 ).
Survival analysis.
The results of the univariate analyses for OS and PFS are listed in Table 2 . Four factors appeared to be associated with OS in univariate analysis: clinical stage, pelvic lymph node (LN) metastases, hysterectomy, and GLUT1 expression. However, all factors except GLUT1 expression were excluded from the Cox proportional hazard model, due to the issue of multicollinearity in relation to GLUT1 expression (all p-value <0.05 by Pearson correlation test). Other than that, age, histology, and tumor grade were entered into the (Table 3) . Kaplan-Meier curves of overall survival based on GLUT1 expression or HPV16 positivity in all study patients were shown in Fig. 1 . Five-year OS rates were 51.7% in GLUT1-high group and 68.7% in GLUT1-low group (p < 0.001).
On the other hand, HPV16 positivity and pelvic LN metastases were significant prognostic factors for PFS in univariate analysis. However, none of them maintained statistical significance in multivariate analysis.
Exploratory subgroup analysis assessing the impact of GLUT1 on. Supplemental Fig. 1 plotted HR and 95% CI after comparing OS based on the GLUT1 expression, between each patient subgroups. The significance of high GLUT1 expression varies depending upon several factors. Specifically, by focusing on HPV16 positivity, the poor prognostic impact of high GLUT1 expression was maintained only in HPV16-positive group (HR 3.326, 95% CI 1.700-6.509, p < 0.001), and not in HPV16-negative group (HR 1.293, 95% CI 0.617-2.708, p = 0.495). Survival curves based on GLUT1 expression and HPV16 status were shown in Fig. 2 .
To further elucidate the cause of the differential impact of GLUT1 overexpression on OS between HPV16-positive and -negative patients, possible differences in the tumor immune microenvironment were investigated. As shown in Table 4 , decreased immune cell scores of T cells, CD8
+ T cells, B cells, Th1 cells, and exhausted CD8
+ cells induced by high GLUT1 expression were observed only in the HPV16-positive group, whereas no significant differences was found in the HPV16-negative group.
Discussion
In the present study, we demonstrated that high GLUT1 expression and HPV16 subtype are independent prognostic factors in cervical cancer. Interestingly, poor prognostic impact as well as differences in the tumor immune microenvironment linked to high GLUT1 expression were observed only in HPV16-positive group.
Characteristics
No. Table 3 . Multivariate analysis of prognostic factors for overall survival. HR, hazard ratio; CI, confidence interval; HPV, human papilloma virus. 18 , and these findings are consistent with our study. These previous studies were based on immunohistochemistry results, which might be subjective, therefore may produce different results. In our study, we quantitatively assessed GLUT1 mRNA expression level since there was no GLUT1 protein expression data in the TCGA database.
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We hypothesized that one of the reasons of the above conflicting results for the prognostic role of GLUT1 in cervical cancer may result from the difference in the proportion of HPV16-positive patients. In our study, HR for high GLUT1 expression was 3.326 in the HPV16-positive group (p < 0.001) and 1.293 in the HPV16-negative group (p = 0.495), showing that the role of GLUT1 may differ depending on HPV16 status. Our study is the first report suggesting a differential prognostic impact of GLUT1 according to the carcinogenic virus type. Carcinogenic viruses can regulate tumor metabolic profiles via direct or indirect interaction with GLUT1
19 . According to above findings, HPV16-related cancer may be more addicted to the glycolysis pathway through its oncoprotein E6/E7, thus GLUT1 expression level could have an important prognostic value in HPV-positive cervical cancer 20, 21 . HPV16 E7 protein can alter the activity of pyruvate kinase, which enables deriving metabolic energy mostly from glycolytic processes rather than from oxidative phosphorylation 20 . Moreover, the expression changes of E6/E7 significantly promote the expression of hypoxia-inducible factor 1-alpha (HIF-1α) which activates the transcription of transporters and enzymes regulating the glycolysis and the pentose phosphate shunt 21 . On the other hand, HPV16-negative tumors may have an alternative metabolic dependency. For example, HPV18 cancers have higher unspliced transcripts of the E6 oncoprotein than HPV16 cancers, suggesting different functional implications of E6 and E7, according to the HPV genotypes 22 . Determining unrevealed prognostic determinants of HPV16-negative cervical cancer would be critical in developing further strategies for enhancing treatment response.
Previous studies estimated that HPV16 accounts for about half of all cervical cancers and HPV18 accounts for an additional 15%, although there are at least 15 known oncogenic HPV types 4, 23, 24 . These proportions are very similar to our patient characteristics shown in Supplemental Table 2 , and this similarities support our presumptive methods' relevance. Several studies suggested that HPV types might be a useful prognostic factor in cervical cancer. Ghong et al. reported that patients with HPV16-positive cancer had better diseaes-free survival (HR 0.41; p = 0.0019) 24 . Schwartz et al. demonstrated that patients with HPV18-related cancers showed higher cervical cancer specific mortality (HR 2.5) compared with those with HPV16-related cancers 3 . Similarly, we found that HPV16 subtype was an independent prognostic factor for OS after adjusting for clinical factors in the multivariate analysis. The reason why HPV16 subtype is associated with a better OS is largely unknown. However, it has been suggested that HPV16-positive cells have increased sensitivity to cancer therapies, a higher level of tumor apoptosis, a slower growth rate, and an enhanced immune response towards the virus in several cancer cells, providing a possible explanation for the increased radiation sensitivity of cervical cancer with HPV16 positivity 25, 26 . To further investigate the phenotype of GLUT1 overexpression in HPV16-positive cervical cancer, we examined the effects of GLUT1 overexpression on tumor immune microenvironment, based on the hypothesis that GLUT1-mediated immune evasion in the HPV16-positive cervical cancer could affect the treatment outcome 27, 28 .
Our results revealed that individual immune cell scores of T cells, CD8
+ T cells, and B cells were significantly reduced in high GLUT1 expression group of HPV16-positive cervical cancer. It is known that metabolic perturbations within tumor induced by high GLUT1 level modulate tumor immune microenvironment by suppressing T cells; this effect is due to a metabolic competition and to the generation of metabolic byproducts 29, 30 . GLUT1-mediated immune escape from cytotoxic T cells of tumor cells may be the cause of reduced survival.
Our results raise the possibility of considering GLUT1 as a potential novel target of HPV16-induced cervical cancer. Similar to the immune checkpoint blockade, strategies to reverse GLUT1-mediated immune escape could also be considered as potential treatment. Clinically, GLUT1 has not been directly targeted since specific and potent inhibitors are still not found 14 . Zhao et al. have shown that the inhibition of GLUT1 by the small-molecule inhibitor WZB117, could increase the radiosensitivity of breast cancer cells 31 . Other novel inhibitors of GLUT1 are under development 14 . The present study has several limitations. First, there is a possibility that the integration of HPV information and the immune cell scores from different studies may be an obstacle in the interpretation of the main grouping, despite they all used the same TCGA data. Second, the generalization of our findings could be restricted by the lack of a suitable external validation cohort. Lastly, the relatively small number of patients as well as the heterogeneity of the treatment modalities might also have affected the prognostic impact of the analyzed variables.
Conclusions
Despite of these limitations, our results suggested that GLUT1 expression and HPV16 subtype might have an independent prognostic value in cervical cancer. This study will provide new hypothesis and strategies for the sensitization of cancer cells to radiotherapy or chemotherapy through the regulation of glucose metabolism. Pre-treatments testing the HPV status may make personalized treatment possible. GLUT1-mediated immunomodulation might be an important cause of treatment failure, especially in the HPV16-positive group; thus, the incorporation of GLUT1 inhibitors may be helpful to increase treatment efficacy. Further proof-of-concept study is warranted to identify novel immunometabolic targets to overcome therapeutic resistance.
Methods
Patient population and data acquisition. All methods were in accordance with the relevant guidelines and regulations, and were approved by the Ethical Review Committee of the Seoul Metropolitan Government Seoul National University Boramae Medical Center. As the data were de-identified in the TCGA database, the ethics committee approved that the requirement of informed consent was waived. This study complied with TCGA publication guidelines and policies (http://cancergenome.nih.gov/publications/publicationguidelines). (2019) 9:13301 | https://doi.org/10.1038/s41598-019-49928-x www.nature.com/scientificreports www.nature.com/scientificreports/ Clinicopathologic factors and mRNA expression data were obtained from TCGA database, using TCGA-biolinks package 32 . Clinical information including tumor stage, tumor histology, disease extent, and treatment course were collected and analyzed. In total, 298 cervical cancer patients with appropriate survival data were included. The sample types of the included patients were all primary solid tumors except for two metastatic tissues.
HPV status and genotype. Tumor HPV status and genotype were determined according to the supplemental information from a previous TCGA publication, which calculated them using MassArray and RNA-sequencing 22 . For patients who did not fulfill the inclusion criteria for the above study, their HPV status and genotype were determined using another previous publication from TCGA, which used the number of normalized reads mapping to each HPV reference (DNA cut-off of 50 normalized counts of HPV aligned reads) 33 .
Immune cell scores. Immune cell scores were extracted from a previous TCGA study, which calculated these scores in 9986 RNASeq samples from 24 different tumor types 34 . Briefly, each immune cell score was calculated from specific 60 marker genes, whose expression levels could classify 14 immune cell populations. These results were highly reproducible and concordant with flow cytometry and immunohistochemistry results 34 .
Statistical analysis.
To compare the clinicopathologic features between two groups, student's t-test and chi-square test were applied to continuous variables and categorical variables, respectively. Using clinical follow-up data version 4.0, the overall survival (OS) and the progression-free survival (PFS) were defined from the date of initial diagnosis to the date of death or the last follow-up and to the date of disease progression, respectively. Survival estimates were calculated by the Kaplan-Meier method and compared using the log-rank test. The dichotomous cut-off point discriminating the OS between GLUT1-high and -low patients, was determined by the maximal chi-square test, which divided all the patients into two groups based on the median z-score of 0.165. Statistically significant factors in univariate analysis were checked for collinearity, using Pearson correlation coefficient. Factors with a p-value < 0.05 on univariate analysis or factors considered clinically important (e.g., HPV16 genotype) were subjected to the multivariate analysis. In multivariate analysis, Cox proportional hazards regression models were applied to adjust the potential confounding effects of associated variables and also were used to calculate hazard ratios (HR) and 95% confidence intervals (CI). R 3.3.0 statistical package (https://www.r-project.org/) was used for all statistical analyses.
Data Availability
The raw datasets of the current study are available in the Supplemental Dataset.
